Paper Details

  1. Home
  2. Paper Details

The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects.

Author: AnHoyoung, ChoiBooyeol, HanSeol-Heui, HongChang Hyung, KimDo-Hoon, KimSeong Yoon, ParkKun-Woo, YangDong-Won

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Escitalopram was well tolerated in patients with depression and Alzheimer's disease. The study did not find statistically significant differences in depression or cognition between the escitalopram and placebo groups after 12 weeks. Further research is needed on a subset of subjects with more severe depression.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Effective treatments to alleviate depression in Alzheimer's disease (AD) have been scarce. OBJECTIVE: To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD. METHODS: In this 12-week randomized, double-blind, placebo-controlled trial with open...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3233/JAD-160225

データ提供：米国国立医学図書館（NLM）

Escitalopram for Depression in Alzheimer's Disease: A Promising But Complex Treatment

We're exploring the complexities of [neuropsychiatry] and its intersection with [Alzheimer's disease]. This study examines the efficacy and safety of [escitalopram], an [selective serotonin reuptake inhibitor (SSRI)], in treating [depression] in patients with [Alzheimer's disease]. It's like navigating a vast and challenging desert, seeking a solution for a dual diagnosis.

Escitalopram's Effects on Depression and Cognition in Alzheimer's Disease

The study found that [escitalopram] was well tolerated by patients with [Alzheimer's disease] and did not lead to any serious adverse events. However, the study did not show statistically significant differences in measures of depression or cognition between the treatment group and the placebo group. While this may seem like a setback, the researchers highlight the need for further research on a subset of patients with more severe depression.

Navigating the Complexities of Treating Depression in Alzheimer's Disease

The study emphasizes the challenge of treating [depression] in patients with [Alzheimer's disease], highlighting the need for more targeted and effective treatments. It's a reminder that the desert of brain health is vast and complex, requiring a multifaceted approach to care.

Dr. Camel's Conclusion

This study offers valuable insights into the use of [escitalopram] in treating [depression] in [Alzheimer's disease]. While more research is needed to determine its optimal use, it's a step in the right direction for finding effective treatments for those grappling with this challenging condition.
Date :
  1. Date Completed 2018-02-22
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

27716660

DOI: Digital Object Identifier

10.3233/JAD-160225

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.